The selective pulmonary vasodilatory effects of inhaled nitric oxide decrease pulmonary artery hypertension and improve arterial oxygenation in patients with ARDS without causing concomitant systemic vasodilation. Inhaled nitrix oxide therapy may decrease the prevalence of pulmonary edema, pulmonary barotrauma, and oxygen toxicity that occur with current ARDS treatment. The effect of nitric oxide on oxygenation and pulmonary artery pressure may allow more time for the lungs to recover. Initial results of clinical trials are encouraging; however, the impact of inhaled nitric oxide therapy on patients with ARDS remains unclear. Further research is needed to develop safe delivery systems and monitoring techniques for routine clinical use, to determine potential adverse and toxic effects of nitric oxide therapy on patients, and to determine the effects of long-term exposure to nitric oxide among healthcare workers. Concomitant administration of other medications with inhaled nitric oxide should also be investigated.
Skip Nav Destination
Article navigation
30 December 1998
Articles|
December 30 1998
Inhaled nitric oxide therapy for adult respiratory distress syndrome
Crit Care Nurse (1998) 18 (6): 21–27.
Citation
CH Burke-Martindale; Inhaled nitric oxide therapy for adult respiratory distress syndrome. Crit Care Nurse 30 December 1998; 18 (6): 21–27. doi: https://doi.org/10.4037/ccn1998.18.6.21
Download citation file:
Sign in
Don't already have an account? Register
Short-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access